Inavolisib API is a pharmaceutical-grade phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor developed for the treatment of PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced breast cancer. It selectively inhibits the PI3Kα signaling pathway, reducing tumor cell proliferation, promoting apoptosis, and overcoming resistance to endocrine therapy.
Inavolisib has demonstrated promising clinical efficacy when used in combination with endocrine therapy and CDK4/6 inhibitors, making it an important advancement in precision oncology and targeted breast cancer treatment.
Manufactured under WHO-GMP-certified facilities, our Inavolisib API is produced using advanced pharmaceutical manufacturing processes to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes comprehensive quality testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.